Abstract
To find a treatment that may be effective against micrometastases of advanced, stage III or IV neuroblastoma, [125I]metaiodobenzylguanidine (125I-MIBG) was used in a phase I toxicity trial. In seven patients, thrombocytopenia was encountered with absorbed whole body doses of 85-135 rad from 125I-MIBG, but the dosimetry was imprecise in predicting bone marrow injury. Three patients survived for over one year, results that may indicate efficacy of 125I-MIBG therapy.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
3-Iodobenzylguanidine
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Child
-
Child, Preschool
-
Drug Evaluation
-
Humans
-
Iodine Radioisotopes / adverse effects
-
Iodine Radioisotopes / therapeutic use*
-
Iodobenzenes / adverse effects
-
Iodobenzenes / therapeutic use*
-
Neuroblastoma / therapy*
-
Thrombocytopenia / etiology
Substances
-
Antineoplastic Agents
-
Iodine Radioisotopes
-
Iodobenzenes
-
3-Iodobenzylguanidine